加载中
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
前收盘价
US$0.6733
−US$0.0479 · -6.64%
盘前
US$0.68
+US$0.0067 · +1.00%
10月13日 4:58 ET
盘中时间采用ET。市场数据可能有所延迟。
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
日内区间
当前US$0.6733
52周区间
当前US$0.6733
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
97
深度低估
情绪
46
多空交织
风险
66
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
日内区间
当前US$0.6733
52周区间
当前US$0.6733
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$9.50
上涨空间 1310.96%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI743.44万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM415.98万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF245.67万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO115.61万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC49.5万0.04%13.17亿 USD0.60%US$181.66-0.73%
iShares Core S&P Total U.S. Stock Market ETFITOT42.64万0.00%980.88亿 USD0.03%US$169.43-0.14%
Virtus Biotech Clinical Trials ETFBBC29.72万0.71%4191.31万 USD0.65%US$43.13-2.30%
Vanguard Russell 2000 Value ETFVTWV18.61万0.01%14亿 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTVirtus Biotech Clinical Trials ETFBBCVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
